Haisco Pharmaceutical (SHE:002653) received approval from China's National Medical Products Administration for its crisugabalin besilate capsules, according to a Tuesday filing with the Shenzhen bourse.
The drug helps treat neuropathic pain in adults.
Shares fell over 2% during the midday break on Tuesday.